CO6270221A2 - "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". - Google Patents
"forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".Info
- Publication number
- CO6270221A2 CO6270221A2 CO10049269A CO10049269A CO6270221A2 CO 6270221 A2 CO6270221 A2 CO 6270221A2 CO 10049269 A CO10049269 A CO 10049269A CO 10049269 A CO10049269 A CO 10049269A CO 6270221 A2 CO6270221 A2 CO 6270221A2
- Authority
- CO
- Colombia
- Prior art keywords
- indazol
- methylphenyl
- fluoro
- urea
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma cristalina 2 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento de pacientes que padecen una enfermedad para usarla. 1.- Forma cristalina 2 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea que, cuando se mide a aproximadamente 25°C con radiacion a 1,54178 , se caracteriza por un patron de difraccion en polvo que tiene valores 2? respectivos de aproximadamente 6,7°, 10,1°, 11,8°, 13,4°, 14,4°, 15,4°, 16,6°, 16,8°, 17,8°, 20,5° y 23,4°.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98126507P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270221A2 true CO6270221A2 (es) | 2011-04-20 |
Family
ID=40174735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10049269A CO6270221A2 (es) | 2007-10-19 | 2010-04-27 | "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7772404B2 (es) |
| EP (1) | EP2195299A1 (es) |
| JP (1) | JP2011500708A (es) |
| KR (1) | KR20100084665A (es) |
| CN (1) | CN101827825B (es) |
| AU (1) | AU2008312534A1 (es) |
| BR (1) | BRPI0818337A2 (es) |
| CA (1) | CA2699356A1 (es) |
| CO (1) | CO6270221A2 (es) |
| CR (1) | CR11444A (es) |
| DO (1) | DOP2010000111A (es) |
| EC (1) | ECSP10010175A (es) |
| GT (1) | GT201000099A (es) |
| MX (1) | MX2010004287A (es) |
| PA (1) | PA8800401A1 (es) |
| RU (1) | RU2010119920A (es) |
| UA (1) | UA99490C2 (es) |
| WO (1) | WO2009052231A1 (es) |
| ZA (1) | ZA201002094B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| WO2016022750A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| CN1826324B (zh) * | 2003-05-22 | 2011-12-07 | 雅培制药有限公司 | 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂 |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| WO2007015578A1 (ja) * | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| WO2007076358A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| JP2010509289A (ja) * | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
-
2008
- 2008-10-15 US US12/251,918 patent/US7772404B2/en not_active Expired - Fee Related
- 2008-10-16 CA CA2699356A patent/CA2699356A1/en not_active Abandoned
- 2008-10-16 KR KR1020107011003A patent/KR20100084665A/ko not_active Application Discontinuation
- 2008-10-16 CN CN2008801119519A patent/CN101827825B/zh not_active Expired - Fee Related
- 2008-10-16 JP JP2010530094A patent/JP2011500708A/ja active Pending
- 2008-10-16 BR BRPI0818337A patent/BRPI0818337A2/pt not_active IP Right Cessation
- 2008-10-16 RU RU2010119920/04A patent/RU2010119920A/ru not_active Application Discontinuation
- 2008-10-16 WO PCT/US2008/080068 patent/WO2009052231A1/en active Application Filing
- 2008-10-16 AU AU2008312534A patent/AU2008312534A1/en not_active Abandoned
- 2008-10-16 UA UAA201006031A patent/UA99490C2/ru unknown
- 2008-10-16 EP EP08839994A patent/EP2195299A1/en not_active Withdrawn
- 2008-10-16 MX MX2010004287A patent/MX2010004287A/es active IP Right Grant
- 2008-10-17 PA PA20088800401A patent/PA8800401A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02094A patent/ZA201002094B/en unknown
- 2010-04-16 DO DO2010000111A patent/DOP2010000111A/es unknown
- 2010-04-16 GT GT201000099A patent/GT201000099A/es unknown
- 2010-04-27 CO CO10049269A patent/CO6270221A2/es not_active Application Discontinuation
- 2010-05-14 EC EC2010010175A patent/ECSP10010175A/es unknown
- 2010-05-19 CR CR11444A patent/CR11444A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP10010175A (es) | 2010-06-29 |
| RU2010119920A (ru) | 2011-11-27 |
| US7772404B2 (en) | 2010-08-10 |
| CN101827825A (zh) | 2010-09-08 |
| MX2010004287A (es) | 2010-04-30 |
| CN101827825B (zh) | 2012-11-21 |
| WO2009052231A1 (en) | 2009-04-23 |
| DOP2010000111A (es) | 2010-07-15 |
| BRPI0818337A2 (pt) | 2017-05-23 |
| ZA201002094B (en) | 2011-11-30 |
| GT201000099A (es) | 2012-03-26 |
| EP2195299A1 (en) | 2010-06-16 |
| CA2699356A1 (en) | 2009-04-23 |
| US20090124816A1 (en) | 2009-05-14 |
| JP2011500708A (ja) | 2011-01-06 |
| UA99490C2 (en) | 2012-08-27 |
| CR11444A (es) | 2010-10-05 |
| PA8800401A1 (es) | 2009-05-15 |
| AU2008312534A1 (en) | 2009-04-23 |
| KR20100084665A (ko) | 2010-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| MY183331A (en) | Crystal form of phenylamino pyrimidine derivatives | |
| UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| CO6270221A2 (es) | "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000116A (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000113A (es) | Productos quimioterapeuticos cristalinos | |
| UY31407A1 (es) | "productos quimioterapéuticos cristalinos" | |
| EA200702590A1 (ru) | Ингибиторы растворимой аденилатциклазы | |
| MX2007010374A (es) | Inhibidor de acat cristalino. | |
| UA108849C2 (xx) | Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетаміду | |
| TH104745B (th) | สารทางเคมีบำบัดที่เป็นผลึก | |
| ECSP10010177A (es) | Productos quimioterapéuticos cristalinos | |
| TH104745A (th) | สารทางเคมีบำบัดที่เป็นผลึก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |